SON-1010

BIOLOGICAL2 trials

Sponsors

Sonnet BioTherapeutics

Conditions

Advanced Solid TumorPlatinum-resistant Ovarian CancerSoft Tissue Sarcoma Adult

Phase 1

Phase 1 Study of SON-1010 in Adult Patients With Advanced Solid Tumors

Active, not recruitingNCT05352750

Sonnet BioTherapeuticsAdvanced Solid Tumor, Soft Tissue Sarcoma Adult

Start: 2022-04-20End: 2026-06-30Updated: 2026-02-03

Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer

TerminatedNCT05756907

Sonnet BioTherapeuticsAdvanced Solid Tumor, Platinum-resistant Ovarian Cancer

Start: 2023-09-15End: 2026-01-08Updated: 2026-02-03

Related Papers

Abstract CT179: SON-1010 (IL12-FHAB) synergizes with trabectedin in advanced soft-tissue sarcoma

Cancer Research2026-04-17

SB221: A proof-of-concept study to assess the combination of SON-1010 (IL12-F<sub>H</sub>AB) and atezolizumab in patients with platinum-resistant ovarian cancer.

Journal of Clinical Oncology2024-06-012 citations